180 related articles for article (PubMed ID: 37824212)
41. Achondroplasia: pathogenesis and implications for future treatment.
Laederich MB; Horton WA
Curr Opin Pediatr; 2010 Aug; 22(4):516-23. PubMed ID: 20601886
[TBL] [Abstract][Full Text] [Related]
42. Theobroma cacao improves bone growth by modulating defective ciliogenesis in a mouse model of achondroplasia.
Martin L; Kaci N; Benoist-Lasselin C; Mondoloni M; Decaudaveine S; Estibals V; Cornille M; Loisay L; Flipo J; Demuynck B; de la Luz Cádiz-Gurrea M; Barbault F; Fernández-Arroyo S; Schibler L; Segura-Carretero A; Dambroise E; Legeai-Mallet L
Bone Res; 2022 Jan; 10(1):8. PubMed ID: 35078974
[TBL] [Abstract][Full Text] [Related]
43. Insulin-like growth factor-1 rescues the mutated FGF receptor 3 (G380R) expressing ATDC5 cells from apoptosis through phosphatidylinositol 3-kinase and MAPK.
Koike M; Yamanaka Y; Inoue M; Tanaka H; Nishimura R; Seino Y
J Bone Miner Res; 2003 Nov; 18(11):2043-51. PubMed ID: 14606518
[TBL] [Abstract][Full Text] [Related]
44. Achondroplasia: from genotype to phenotype.
Richette P; Bardin T; Stheneur C
Joint Bone Spine; 2008 Mar; 75(2):125-30. PubMed ID: 17950653
[TBL] [Abstract][Full Text] [Related]
45. Gain-of-function mutation in FGFR3 in mice leads to decreased bone mass by affecting both osteoblastogenesis and osteoclastogenesis.
Su N; Sun Q; Li C; Lu X; Qi H; Chen S; Yang J; Du X; Zhao L; He Q; Jin M; Shen Y; Chen D; Chen L
Hum Mol Genet; 2010 Apr; 19(7):1199-210. PubMed ID: 20053668
[TBL] [Abstract][Full Text] [Related]
46. Multikinase activity of fibroblast growth factor receptor (FGFR) inhibitors SU5402, PD173074, AZD1480, AZD4547 and BGJ398 compromises the use of small chemicals targeting FGFR catalytic activity for therapy of short-stature syndromes.
Gudernova I; Vesela I; Balek L; Buchtova M; Dosedelova H; Kunova M; Pivnicka J; Jelinkova I; Roubalova L; Kozubik A; Krejci P
Hum Mol Genet; 2016 Jan; 25(1):9-23. PubMed ID: 26494904
[TBL] [Abstract][Full Text] [Related]
47. A Ser(365)-->Cys mutation of fibroblast growth factor receptor 3 in mouse downregulates Ihh/PTHrP signals and causes severe achondroplasia.
Chen L; Li C; Qiao W; Xu X; Deng C
Hum Mol Genet; 2001 Mar; 10(5):457-65. PubMed ID: 11181569
[TBL] [Abstract][Full Text] [Related]
48. Novel therapeutic approaches for the treatment of achondroplasia.
Legeai-Mallet L; Savarirayan R
Bone; 2020 Dec; 141():115579. PubMed ID: 32795681
[TBL] [Abstract][Full Text] [Related]
49. Severe achondroplasia due to two de novo variants in the transmembrane domain of FGFR3 on the same allele: A case report.
Nagata T; Matsushita M; Mishima K; Kamiya Y; Kato K; Toyama M; Ogi T; Ishiguro N; Kitoh H
Mol Genet Genomic Med; 2020 Mar; 8(3):e1148. PubMed ID: 31975530
[TBL] [Abstract][Full Text] [Related]
50. Long-term oral meclozine administration improves survival rate and spinal canal stenosis during postnatal growth in a mouse model of achondroplasia in both sexes.
Funahashi H; Matsushita M; Esaki R; Mishima K; Ohkawara B; Kamiya Y; Takegami Y; Ohno K; Kitoh H; Imagama S
JBMR Plus; 2024 Apr; 8(4):ziae018. PubMed ID: 38544920
[TBL] [Abstract][Full Text] [Related]
51. Mild achondroplasia/hypochondroplasia with acanthosis nigricans, normal development, and a p.Ser348Cys FGFR3 mutation.
Couser NL; Pande CK; Turcott CM; Spector EB; Aylsworth AS; Powell CM
Am J Med Genet A; 2017 Apr; 173(4):1097-1101. PubMed ID: 28181399
[TBL] [Abstract][Full Text] [Related]
52. Mouse models orthologous to FGFR3-related skeletal dysplasias.
Brodie SG; Deng CX
Pediatr Pathol Mol Med; 2003; 22(1):87-103. PubMed ID: 12687892
[TBL] [Abstract][Full Text] [Related]
53. FGFR3/fibroblast growth factor receptor 3 inhibits autophagy through decreasing the ATG12-ATG5 conjugate, leading to the delay of cartilage development in achondroplasia.
Wang X; Qi H; Wang Q; Zhu Y; Wang X; Jin M; Tan Q; Huang Q; Xu W; Li X; Kuang L; Tang Y; Du X; Chen D; Chen L
Autophagy; 2015 Nov; 11(11):1998-2013. PubMed ID: 26491898
[TBL] [Abstract][Full Text] [Related]
54. Effect of the achondroplasia mutation on FGFR3 dimerization and FGFR3 structural response to fgf1 and fgf2: A quantitative FRET study in osmotically derived plasma membrane vesicles.
Sarabipour S; Hristova K
Biochim Biophys Acta; 2016 Jul; 1858(7 Pt A):1436-42. PubMed ID: 27040652
[TBL] [Abstract][Full Text] [Related]
55. [From gene to disease; achondroplasia and other skeletal dysplasias due to an activating mutation in the fibroblast growth factor].
van Ravenswaaij-Arts CM; Losekoot M
Ned Tijdschr Geneeskd; 2001 Jun; 145(22):1056-9. PubMed ID: 11414167
[TBL] [Abstract][Full Text] [Related]
56. Skeletal overgrowth and deafness in mice lacking fibroblast growth factor receptor 3.
Colvin JS; Bohne BA; Harding GW; McEwen DG; Ornitz DM
Nat Genet; 1996 Apr; 12(4):390-7. PubMed ID: 8630492
[TBL] [Abstract][Full Text] [Related]
57. FGFR3 heterodimerization in achondroplasia, the most common form of human dwarfism.
He L; Shobnam N; Wimley WC; Hristova K
J Biol Chem; 2011 Apr; 286(15):13272-81. PubMed ID: 21324899
[TBL] [Abstract][Full Text] [Related]
58. NF449 is a novel inhibitor of fibroblast growth factor receptor 3 (FGFR3) signaling active in chondrocytes and multiple myeloma cells.
Krejci P; Murakami S; Prochazkova J; Trantirek L; Chlebova K; Ouyang Z; Aklian A; Smutny J; Bryja V; Kozubik A; Wilcox WR
J Biol Chem; 2010 Jul; 285(27):20644-53. PubMed ID: 20439987
[TBL] [Abstract][Full Text] [Related]
59. Functional characteristics of mesenchymal stem cells derived from the adipose tissue of a patient with achondroplasia.
Park JR; Lee H; Kim CH; Hong SH; Ha KS; Yang SR
In Vitro Cell Dev Biol Anim; 2016 May; 52(5):545-54. PubMed ID: 27059327
[TBL] [Abstract][Full Text] [Related]
60. Nordihydroguaiaretic acid inhibits an activated fibroblast growth factor receptor 3 mutant and blocks downstream signaling in multiple myeloma cells.
Meyer AN; McAndrew CW; Donoghue DJ
Cancer Res; 2008 Sep; 68(18):7362-70. PubMed ID: 18794123
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
